(NASDAQ: PLRX) Pliant Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 57.55%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.9%.
Pliant Therapeutics's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast PLRX's revenue for 2027 to be $11,680,580,978, with the lowest PLRX revenue forecast at $11,680,580,978, and the highest PLRX revenue forecast at $11,680,580,978. On average, 2 Wall Street analysts forecast PLRX's revenue for 2028 to be $25,634,909,693, with the lowest PLRX revenue forecast at $8,387,207,163, and the highest PLRX revenue forecast at $42,882,612,222.
In 2029, PLRX is forecast to generate $59,319,708,951 in revenue, with the lowest revenue forecast at $37,310,579,768 and the highest revenue forecast at $81,328,838,134.